Physician profile
Mary Hadad
NPI 1619553815
$5,928.08
in general payments reported to CMS, 2019-2025
23 companies · $933 in 2025
The $933 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $1,356 · 2023: $1,473 · 2024: $1,592 · 2025: $933.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,998.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,135.49 | 2021-2025 | |
| Alkermes, INC. | $574.16 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Corium, LLC | $531.00 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $493.40 | 2023-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $440.32 | 2021-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $295.76 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Ironshore Pharmaceuticals INC. | $295.14 | 2022-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $284.07 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $245.57 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Neuronetics, INC. | $222.76 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $207.37 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $195.49 | 2021-2022 | |
| Axsome Therapeutics, INC. | $187.81 | 2023-2025 | Auvelity |
| Almatica Pharma LLC | $170.35 | 2021-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $161.91 | 2024-2025 | Fanapt, Hetlioz |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $156.01 | 2024 | |
| Lundbeck LLC | $83.95 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $79.88 | 2023 | Quviviq |
| Collegium Pharmaceutical, INC. | $67.69 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $32.73 | 2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $31.31 | 2025 | Cobenfy |
| Bausch Health US, LLC | $19.88 | 2023 | Wellbutrin, Aplenzin |
| Adlon Therapeutics L.P. | $16.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Hadad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.